GPX4 and cardiac hypertrophy: As shown in Figures 9F, G, K, L, when the FSP1 and/or GPX4 pathways were blocked, compared to when DHODH was not inhibited, inhibiting DHODH aggravated myocardial hypertrophy and myocardial fibrosis.